VeriSIM Life

14/10/2025

We’re proud to see Dr. Jo Varshney, Founder & CEO of VeriSIM Life, featured in Women Story’s series on entrepreneurial mindsets among women founders.

Fresh off winning the 2025 International Women Entrepreneur Award in IT from Great Companies, Dr. Varshney shared her perspective on leadership and innovation:

“Don’t shy away from science or technology. Your uniqueness is your strength. Innovation thrives on diverse perspectives; own your voice, ask boldly, and claim your place at the table. You belong there.”

Read the full feature here: https://hubs.li/Q03NygDj0

09/10/2025

The NIH’s groundbreaking shift to prioritize human-relevant science marks a paradigm change for biomedical research institutions. Check out our new toolkit that outlines how VeriSIM Life’s BIOiSIM® platform enables researchers to align with NIH’s new direction, replacing traditional animal testing with predictive, clinically relevant AI-driven tools.

For institutions, this shift doesn’t just improve science—it enhances funding competitiveness, reduces R&D costs, and accelerates translational impact.

➡️ Read the Blog: https://hubs.li/Q03MYwpL0
➡️ Download the Full NIH Toolkit: https://hubs.li/Q03MYxMD0

06/10/2025

🚨 Exciting News! 🚨

We’re honored to share that VeriSIM Life has been named a finalist for the Innovation Award in the 2025 Scrip Awards! 🏆✨

This recognition underscores our commitment to transforming drug development with our BIOiSIM® platform, accelerating safe and effective therapies to patients while reducing reliance on animal testing. 💡🐾➡️👩‍⚕️

But innovation is more than technology—it’s about rethinking what’s possible.
👉 How can AI-driven approaches reshape the future of medicine?
👉 What would it mean for patients if we could bring life-saving treatments to market faster and more ethically?

We’re proud to be leading this charge and grateful for the recognition of our vision. 🌍💙

01/10/2025

We’re proud to share that VeriSIM Life has been named a finalist for the Reuters AI in Action award category at the 2025 Pharma Awards! 🎉

This recognition highlights our commitment to reducing patient burden and driving equity in drug development through our BIOiSIM® platform. By creating predictive “digital twin” models of diverse patient populations, BIOiSIM helps drug developers:

✅ Detect safety risks earlier
✅ Reduce unnecessary trials and patient exposure
✅ Design more inclusive and equitable studies
✅ Accelerate access to life-saving therapies

While our work often happens behind the scenes, its impact is deeply human—ensuring patients, especially those in underserved communities, are considered and protected from the very beginning of the R&D process.

We’re honored to be recognized alongside other innovators who are shaping the future of patient-first medicine, and we look forward to the awards ceremony later this year.

👉 Read more: https://hubs.li/Q03LLdVB0

26/09/2025

🚀 Exciting news! VeriSIM Life has been featured in Drug Discovery News in an article titled “From Preclinical to Clinic Faster with Mechanistic Modeling and AI”. Jo Varshney, our Founder & CEO, shares how BIOiSIM® is helping to shorten timelines, reduce risk, and improve decision-making in early drug development.

With BIOiSIM®, we’re pushing beyond traditional AI tools — integrating mechanistic modeling, virtual populations, and our proprietary Translational Index™ to deliver human-relevant insights into ADME/Tox, dosing, and efficacy. We believe that by combining these methods, we can both accelerate go/no-go decisions and improve chances of success in the clinic.

What do you think are the biggest roadblocks today to adopting model-informed drug development across the industry? And in your view, which therapeutic areas or modalities are most ripe for disruption by human-relevant simulations and hybrid modeling?

🔗 Read more here:

Jo Varshney explains how human-relevant models and mechanistic simulations are transforming early-stage drug discovery and development.

23/09/2025

🎙️Exciting news! Dr. Jo Varshney will be featured in the Flybridge 100 Women in AI Podcast!

After being named to the 100 Women in AI list by Flybridge, Dr. Varshney is joining the podcast to share her journey — the challenges, breakthroughs, and bold ideas that are shaping the future of AI.

From cutting-edge technical insights to real-world impact, her episode will dive deep into the work she's leading, her vision for responsible AI, and the pivotal moments that have shaped her career.

This limited-run series is all about amplifying the voices of women driving innovation, and we’re thrilled to see Dr. Varshney’s story celebrated.

🎧Stay tuned for the link in October!

08/09/2025

📰 Our latest op-ed in Marksmen Daily: https://hubs.li/Q03HlfyG0

At VeriSIM Life, we believe Hybrid AI is transforming drug development—speeding up candidate design, screening, and safety evaluation like never before. But with this acceleration comes a higher responsibility: ensuring transparency, traceability, and trust.

In our piece, we emphasize that innovation must go hand-in-hand with safety and public confidence. Hybrid AI isn’t just about moving faster, it’s about raising the safety bar for the entire industry.

Hybrid AI is accelerating drug development, but experts say transparency will be key to ensuring safety and building public trust.

02/09/2025

🚀 Excited to share a 𝗳𝗶𝗿𝘀𝘁-𝗼𝗳-𝗶𝘁𝘀-𝗸𝗶𝗻𝗱 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 from VeriSIM Life alongside Dr. Weida Tong!

We’ve pioneered a novel AI-driven framework to predict 𝗱𝗿𝘂𝗴-𝗶𝗻𝗱𝘂𝗰𝗲𝗱 𝗹𝗶𝘃𝗲𝗿 𝗶𝗻𝗷𝘂𝗿𝘆 (𝗗𝗜𝗟𝗜) — one of the leading causes of drug development failure and post-market withdrawals.

What makes this groundbreaking? We combined:

🔬 𝗥𝗮𝘁 𝗹𝗶𝘃𝗲𝗿 𝘁𝗿𝗮𝗻𝘀𝗰𝗿𝗶𝗽𝘁𝗼𝗺𝗶𝗰𝘀 – capturing rich biological signals
⚛️ 𝗤𝘂𝗮𝗻𝘁𝘂𝗺 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝗰𝘀-𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝘀 – understanding drug behavior at a fundamental level
🧬 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗱𝗮𝘁𝗮 – reflecting real-world patient diversity

By mechanistically integrating these data streams, our models achieve dramatically improved performance 𝗲𝘃𝗲𝗻 𝘄𝗶𝘁𝗵 𝗹𝗶𝗺𝗶𝘁𝗲𝗱 𝗱𝗮𝘁𝗮𝘀𝗲𝘁𝘀.

👉 This isn’t just about better early safety assessment. It’s a 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 that sets the stage for evaluating efficacy, safety, and target engagement far earlier in the preclinical pipeline.

This work highlights the 𝗽𝗼𝘄𝗲𝗿 𝗼𝗳 𝗰𝗼𝗺𝗯𝗶𝗻𝗶𝗻𝗴 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝘁𝗶𝗰 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝘄𝗶𝘁𝗵 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗔𝗜 to reshape how the industry tackles some of its toughest translational challenges.

We are proud of the VeriSIM Life team for pushing the boundaries of what’s possible in drug development.

Check out the paper: https://hubs.li/Q03Gzsrg0

28/08/2025

🚀 Big News from VeriSIM Life!

We're thrilled to share that our Founder & CEO, Dr. Jo Varshney, has been awarded the 2025 International Women Entrepreneur Award in IT by Great Companies! 🏆🎉

This prestigious recognition honors visionary women who are redefining what's possible in the tech world, and Dr. Varshney is doing just that by leading innovation at the intersection of AI and biotechnology.

At the heart of this achievement is BIOiSIM™, our cutting-edge biosimulation platform that uses predictive modeling to simulate drug behavior in humans — reducing cost, time, and risk in drug development. 💊⚙️

👏 "This recognition is a testament not just to the technology we’ve built, but to the bold, interdisciplinary team that drives VeriSIM Life forward every day," said Dr. Varshney.

Since our founding in 2017, we've been on a mission to make drug development more humane, efficient, and effective — and this award highlights how far we've come.

Read the announcement: https://hubs.li/Q03G6wsl0

💡 What will it take to ensure more women not only enter but lead the next frontier of AI and biotech innovation? We'd love to hear your thoughts.👇

18/08/2025

🎉 Dr. Jo Varshney, a distinguished alumna who earned her PhD from the University of Minnesota, recently participated in two impactful panel discussions during the University's Bay Area Gatherings in Berkeley and Palo Alto! 🎓📍

As the Founder & CEO of VeriSIM Life and a leader in AI-driven healthcare innovation, Dr. Varshney brought powerful insights to the conversation, highlighting how cutting-edge technologies like artificial intelligence are shaping the future of life sciences and transforming drug development. 💡🧬

She joined fellow thought leaders and University of Minnesota President Dr. Rebecca Cunningham in celebrating the university’s legacy of research, education, and real-world impact.

This is just one look at the inspiring moments from these dynamic events! 📸

23/07/2025

Dr. Jo Varshney, Founder & CEO of VeriSIM Life, is guest lecturing at University of Pennsylvania's prestigious ITMAT program alongside Dr. Jeff Barrett, VP at Genmab, as part of the graduate course “Drug Development Decision Criteria.”

Dr. Varshney will lead the session “Opportunities for Artificial Intelligence in Drug Development Decision Making,” followed by a hands-on lab that explores how AI is transforming decisions from discovery through commercialization.

This ITMAT course at UPenn dives into key inflection points across the drug development lifecycle and examines how advanced technologies especially AI and simulation are reshaping the way we bring effective therapies to patients.

Dr. Varshney is proud to represent VeriSIM Life and share our work at the intersection of translational science and AI!

21/07/2025

🚀 VeriSIM Life is proud to be featured in BioTuesdays for our work transforming drug development with AI-powered predictive modeling!

Our CEO, Dr. Jo Varshney, shares how BIOiSIM® is helping researchers make smarter, faster decisions—reducing costs, cutting timelines, and improving clinical outcomes.

Read the full story: https://hubs.li/Q03y3Z1s0